Abstract
Dyslipidemia, arterial hypertension, smoking and type 2 diabetes mellitus are the most important risk factors for cardiovascular disease, therefore LDL-cholesterol reduction is the basis approach in the prevention and treatment of atherosclerotic cardiovascular disease. The first step in treatment is a healthy lifestyle including diet and physical activity, but according to 2016 EAS/ESC Guidelines on management of dyslipidaemias, in addition to reducing the consumption of saturated and trans-unsaturated fatty acids and increasing fiber consumption, the using functional foods rich in phytosterols or nutraceuticals containing red yeast rice could be considered.
The ArmoLIPID PLUS, containing red yeast rice extract, berberin and policosanol, has proved to be able to achieve significant reductions in LDL-cholesterol (15-31,7 %) levels and to decrease glycemia. ArmoLIPID PLUS has been able to change the size and density of LDL particles in patients with familial combined hyperlipoproteinemia.
The primary indication of ArmoLIPID PLUS is in particular in statin intolerant patients, in combination with other non-statin lipid lowering therapy, could be recommended for patients with low and moderate cardiovascular risk in order to delay the atherosclerosis manifestation too.